Pozen Inc. v. Par Pharmaceutical, Inc.: “Fuzzy” limitations and the doctrine of equivalents.
- Published in:
- Journal of Generic Medicines, 2013, v. 10, n. 2, p. 139, doi. 10.1177/1741134313515666
- By:
- Publication type:
- Article
Works matching DE "POZEN Inc."
Results: 8
1
2
POZEN enters into settlement agreement with Teva.
- Published in:
- Journal of Intellectual Property Rights, 2010, v. 15, n. 3, p. 255
- Publication type:
- Article
3
NOT ENOUGH BENEFITS SEEN IN POZEN'S MIGRAINE CANDIDATE, SAY FDA EXPERTS.
- Published in:
- Applied Clinical Trials, 2005, v. 14, n. 9, p. 21
- Publication type:
- Article
4
Market watch.
- Published in:
- Nature, 2006, v. 443, n. 7109, p. 259, doi. 10.1038/443259b
- Publication type:
- Article
5
MT 300 – POZEN: Dihydroergotamine Mesylate Injection.
- Published in:
- Drugs in R&D, 2003, v. 4, n. 6, p. 376
- By:
- Publication type:
- Article
6
MT 300: Dihydroergotamine Mesylate Injection - POZEN.
- Published in:
- Drugs in R&D, 2003, v. 4, n. 2, p. 133
- Publication type:
- Article
7
MT 300: Dihydroergotamine Mesylate Injection - POZEN.
- Published in:
- Drugs in R&D, 2003, v. 4, n. 2, p. 133
- Publication type:
- Article
8
Mt 100.
- Published in:
- Drugs in R&D, 2003, v. 4, n. 1, p. 57, doi. 10.2165/00126839-200304010-00011
- Publication type:
- Article